Zai Lab Stock Forecast, Price & News

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Zai Lab in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Zai Lab stock.
View analyst ratings for Zai Lab or view top-rated stocks.

Wall Street analysts have given Zai Lab a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Zai Lab wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Zai Lab saw a increase in short interest in July. As of July 30th, there was short interest totaling 2,650,000 shares, an increase of 20.5% from the July 15th total of 2,200,000 shares. Based on an average daily trading volume, of 528,400 shares, the short-interest ratio is presently 5.0 days. Approximately 2.8% of the company's stock are short sold.
View Zai Lab's Short Interest.

Zai Lab Limited (NASDAQ:ZLAB) released its quarterly earnings results on Monday, August, 9th. The company reported ($1.76) earnings per share for the quarter, missing the consensus estimate of ($1.55) by $0.21. The firm had revenue of $36.94 million for the quarter, compared to analyst estimates of $24.20 million.
View Zai Lab's earnings history.

Zai Lab's stock was trading at $50.13 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ZLAB shares have increased by 153.4% and is now trading at $127.05.
View which stocks have been most impacted by COVID-19.

4 brokerages have issued 1-year target prices for Zai Lab's shares. Their forecasts range from $111.00 to $250.00. On average, they expect Zai Lab's share price to reach $199.85 in the next twelve months. This suggests a possible upside of 57.3% from the stock's current price.
View analysts' price targets for Zai Lab or view top-rated stocks among Wall Street analysts.

Some companies that are related to Zai Lab include BeiGene (BGNE), Astellas Pharma (ALPMY), MERCK Kommanditgesellschaft auf Aktien (MKGAF), Shiseido (SSDOY), Genmab A/S (GMAB), Genmab A/S (GNMSF), Takeda Pharmaceutical (TKPYY), Horizon Therapeutics Public (HZNP), Catalent (CTLT), Royalty Pharma (RPRX), Alnylam Pharmaceuticals (ALNY), UCB (UCBJF), Viatris (VTRS), Elanco Animal Health (ELAN) and BioMarin Pharmaceutical (BMRN).
View all of ZLAB's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Zai Lab investors own include NVIDIA (NVDA), CRISPR Therapeutics (CRSP), Inseego (INSG), Niu Technologies (NIU), JD.com (JD), Bilibili (BILI), Marvell Technology (MRVL), Baidu (BIDU), BioXcel Therapeutics (BTAI) and Baozun (BZUN).

(ZLAB) raised $100 million in an initial public offering (IPO) on Wednesday, September 20th 2017. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Citigroup and Leerink Partners served as the underwriters for the IPO.

Zai Lab trades on the NASDAQ under the ticker symbol "ZLAB."

Zai Lab's stock is owned by a number of retail and institutional investors. Top institutional shareholders include FMR LLC (4.65%), Baillie Gifford & Co. (4.26%), BlackRock Inc. (4.11%), Brilliance Asset Management Ltd. (3.31%), Vanguard Group Inc. (2.24%) and Federated Hermes Inc. (2.14%). Company insiders that own Zai Lab stock include Harald Reinhart, John D Diekman, Kai-Xian Chen, Tao Fu, William Ki Chul Cho and Ying Du.
View institutional ownership trends for Zai Lab.

ZLAB stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Credit Suisse AG, Indus Capital Partners LLC, Bamco Inc. NY, Mackenzie Financial Corp, Schonfeld Strategic Advisors LLC, Tobam, and California Public Employees Retirement System. Company insiders that have sold Zai Lab company stock in the last year include Harald Reinhart, John D Diekman, Kai-Xian Chen, Tao Fu, William Ki Chul Cho, and Ying Du.
View insider buying and selling activity for Zai Lab or view top insider-selling stocks.

ZLAB stock was acquired by a variety of institutional investors in the last quarter, including Invesco Ltd., FMR LLC, TT International Asset Management LTD, Axiom Investors LLC DE, Brilliance Asset Management Ltd., Clearbridge Investments LLC, Allianz Asset Management GmbH, and Van ECK Associates Corp.
View insider buying and selling activity for Zai Lab or or view top insider-buying stocks.

Shares of ZLAB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ZLAB stock can currently be purchased for approximately $127.05.

Zai Lab has a market capitalization of $12.12 billion and generates $48.96 million in revenue each year. The company earns $-268,900,000.00 in net income (profit) each year or ($3.46) on an earnings per share basis.

Zai Lab employs 2,020 workers across the globe.

The official website for Zai Lab is www.zailaboratory.com.

Zai Lab is headquartered at 4560 JINKE ROAD BLDG. 1 FOURTH FLOOR PUDONG, SHANGHAI F4, 201210.

Zai Lab's mailing address is 4560 JINKE ROAD BLDG. 1 FOURTH FLOOR PUDONG, SHANGHAI F4, 201210. The company can be reached via phone at 862161632588 or via email at [email protected]